Design Therapeutics reports Q4 EPS (24c), consensus (27c)

“Thanks to the progress we have achieved so far this year, the first half of 2025 will be a busy one for Design, with data expected from our Phase 1 trial in FECD and the advancement of clinical activities in our FA program,” said Pratik Shah, CEO. “We believe these programs lead a pipeline of GeneTAC small molecules capable of transforming the status quo in genomic medicines, with the potential for multiple clinical proof-of-concept data sets over the next few years.”